PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23942212-3	2013	In this study, we compared the therapeutic efficacy of Doxil( ) (commercial doxorubicin-loaded liposomes) and that of Doxil( ) conjugated with anti-CD30 antibodies (CD30-targeted Doxil( )) in treating anaplastic large cell lymphoma (ALCL), a type of T-cell lymphoma characterized by a high CD30 expression.	liposomal doxorubicin	118-123	tumor necrosis factor receptor superfamily, member 8	Mus musculus	148-152	
23942212-3	2013	In this study, we compared the therapeutic efficacy of Doxil( ) (commercial doxorubicin-loaded liposomes) and that of Doxil( ) conjugated with anti-CD30 antibodies (CD30-targeted Doxil( )) in treating anaplastic large cell lymphoma (ALCL), a type of T-cell lymphoma characterized by a high CD30 expression.	liposomal doxorubicin	118-123	tumor necrosis factor receptor superfamily, member 8	Mus musculus	165-169	
23942212-3	2013	In this study, we compared the therapeutic efficacy of Doxil( ) (commercial doxorubicin-loaded liposomes) and that of Doxil( ) conjugated with anti-CD30 antibodies (CD30-targeted Doxil( )) in treating anaplastic large cell lymphoma (ALCL), a type of T-cell lymphoma characterized by a high CD30 expression.	liposomal doxorubicin	118-123	tumor necrosis factor receptor superfamily, member 8	Mus musculus	165-169	
23942212-3	2013	In this study, we compared the therapeutic efficacy of Doxil( ) (commercial doxorubicin-loaded liposomes) and that of Doxil( ) conjugated with anti-CD30 antibodies (CD30-targeted Doxil( )) in treating anaplastic large cell lymphoma (ALCL), a type of T-cell lymphoma characterized by a high CD30 expression.	liposomal doxorubicin	118-123	tumor necrosis factor receptor superfamily, member 8	Mus musculus	148-152	
23942212-3	2013	In this study, we compared the therapeutic efficacy of Doxil( ) (commercial doxorubicin-loaded liposomes) and that of Doxil( ) conjugated with anti-CD30 antibodies (CD30-targeted Doxil( )) in treating anaplastic large cell lymphoma (ALCL), a type of T-cell lymphoma characterized by a high CD30 expression.	liposomal doxorubicin	118-123	tumor necrosis factor receptor superfamily, member 8	Mus musculus	165-169	
23942212-3	2013	In this study, we compared the therapeutic efficacy of Doxil( ) (commercial doxorubicin-loaded liposomes) and that of Doxil( ) conjugated with anti-CD30 antibodies (CD30-targeted Doxil( )) in treating anaplastic large cell lymphoma (ALCL), a type of T-cell lymphoma characterized by a high CD30 expression.	liposomal doxorubicin	118-123	tumor necrosis factor receptor superfamily, member 8	Mus musculus	165-169	
23942212-4	2013	Compared to Doxil( ), the CD30-targeted Doxil( ) showed a significantly higher binding affinity to ALCL cells (5.3% versus 27%, p = 0.005) and a lower inhibitory concentration at 50% (IC50) in-vitro (32.6 mug/mL versus 12.6 mug/mL, p = 0.006).	liposomal doxorubicin	12-17	tumor necrosis factor receptor superfamily, member 8	Mus musculus	26-30	
23942212-4	2013	Compared to Doxil( ), the CD30-targeted Doxil( ) showed a significantly higher binding affinity to ALCL cells (5.3% versus 27%, p = 0.005) and a lower inhibitory concentration at 50% (IC50) in-vitro (32.6 mug/mL versus 12.6 mug/mL, p = 0.006).	liposomal doxorubicin	40-45	tumor necrosis factor receptor superfamily, member 8	Mus musculus	26-30	
23942212-5	2013	In a SCID mouse xenograft model, CD30-targeted Doxil( ) inhibited tumor growth more significantly than the unconjugated formulation; specifically, tumors in mice treated with CD30-targeted Doxil( ) were significantly smaller than those in mice treated with Doxil( ) (average, 117 mm(3) versus 270 mm(3), p = 0.001) at 18 days after the tumors were inoculated.	liposomal doxorubicin	47-52	tumor necrosis factor receptor superfamily, member 8	Mus musculus	33-37	
23942212-5	2013	In a SCID mouse xenograft model, CD30-targeted Doxil( ) inhibited tumor growth more significantly than the unconjugated formulation; specifically, tumors in mice treated with CD30-targeted Doxil( ) were significantly smaller than those in mice treated with Doxil( ) (average, 117 mm(3) versus 270 mm(3), p = 0.001) at 18 days after the tumors were inoculated.	liposomal doxorubicin	47-52	tumor necrosis factor receptor superfamily, member 8	Mus musculus	175-179	
23942212-5	2013	In a SCID mouse xenograft model, CD30-targeted Doxil( ) inhibited tumor growth more significantly than the unconjugated formulation; specifically, tumors in mice treated with CD30-targeted Doxil( ) were significantly smaller than those in mice treated with Doxil( ) (average, 117 mm(3) versus 270 mm(3), p = 0.001) at 18 days after the tumors were inoculated.	liposomal doxorubicin	189-194	tumor necrosis factor receptor superfamily, member 8	Mus musculus	33-37	
23942212-5	2013	In a SCID mouse xenograft model, CD30-targeted Doxil( ) inhibited tumor growth more significantly than the unconjugated formulation; specifically, tumors in mice treated with CD30-targeted Doxil( ) were significantly smaller than those in mice treated with Doxil( ) (average, 117 mm(3) versus 270 mm(3), p = 0.001) at 18 days after the tumors were inoculated.	liposomal doxorubicin	189-194	tumor necrosis factor receptor superfamily, member 8	Mus musculus	175-179	
23942212-5	2013	In a SCID mouse xenograft model, CD30-targeted Doxil( ) inhibited tumor growth more significantly than the unconjugated formulation; specifically, tumors in mice treated with CD30-targeted Doxil( ) were significantly smaller than those in mice treated with Doxil( ) (average, 117 mm(3) versus 270 mm(3), p = 0.001) at 18 days after the tumors were inoculated.	liposomal doxorubicin	189-194	tumor necrosis factor receptor superfamily, member 8	Mus musculus	33-37	
23942212-5	2013	In a SCID mouse xenograft model, CD30-targeted Doxil( ) inhibited tumor growth more significantly than the unconjugated formulation; specifically, tumors in mice treated with CD30-targeted Doxil( ) were significantly smaller than those in mice treated with Doxil( ) (average, 117 mm(3) versus 270 mm(3), p = 0.001) at 18 days after the tumors were inoculated.	liposomal doxorubicin	189-194	tumor necrosis factor receptor superfamily, member 8	Mus musculus	175-179